Detalhe da pesquisa
1.
Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
J Immunol
; 193(4): 1920-30, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25024381
2.
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
Am J Respir Crit Care Med
; 188(4): 492-502, 2013 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23306546
3.
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Clin Infect Dis
; 52(4): 522-31, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21208909
4.
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.
NPJ Vaccines
; 6(1): 78, 2021 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021167
5.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 20(6): 719-730, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199492
6.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 20(6): 707-718, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199491
7.
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
NPJ Vaccines
; 3: 13, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29582861
8.
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
NPJ Vaccines
; 2: 25, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263880
9.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
Curr Opin Virol
; 17: 57-65, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827165
10.
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.
Medicine (Baltimore)
; 95(6): e2673, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26871794
11.
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
PLoS One
; 10(5): e0125954, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25961283
12.
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
Clin Vaccine Immunol
; 21(3): 302-11, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24391139
13.
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
Vaccine
; 32(22): 2657-65, 2014 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24144472
14.
Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients.
J Immunol Methods
; 414: 1-10, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25224748
15.
Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques.
Naunyn Schmiedebergs Arch Pharmacol
; 385(12): 1211-25, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22983013
16.
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
J Acquir Immune Defic Syndr
; 59(1): 1-9, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21963936
17.
Vaccine-induced HIV seropositivity: a problem on the rise.
J Clin Virol
; 50(4): 334-7, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21300566
18.
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.
Vaccine
; 29(13): 2461-73, 2011 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21256188
19.
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Vaccine
; 28(43): 7016-24, 2010 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20728522
20.
Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.
Vaccine
; 26(8): 1072-82, 2008 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18258343